Oncology · PIK3CA-mutant Breast CancerTrial Updateclinicalmid-term

Phase I Study of Inavolisib in PIK3CA-Mutant Solid Tumors and Breast Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/4/2026, 6:32:18 AM

Assessment confidence: 79% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase I trial of inavolisib represents a significant development in the treatment landscape for PIK3CA-mutant breast cancer, a critical area of oncology. Monitoring the trial's outcomes is essential as it may influence treatment protocols and competitive positioning in this therapeutic area. Regulatory context from FDA (Cancer Clinical Trial Eligibility Criteria: Laboratory Values) supports the near-term read. Assessment grounded in 6 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should monitor inavolisib's progress as it may enhance treatment options for PIK3CA-mutant breast cancer. The strongest clinical anchor is An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov), sub-indication match (breast cancer); entity match (fulvestrant). Successful trial outcomes could enhance market share for inavolisib and its combinations, potentially leading to increased revenue streams in a competitive oncology market.

Competitive Pressure

The most relevant competitive pressure comes from This trial positions inavolisib as a potential treatment option in a competitive landscape of targeted therapies for breast cancer..

Regulatory Outlook

Regulatory risk is concentrated around The trial's results will be pivotal for future regulatory submissions and could affect labeling and compliance requirements for inavolisib and its combinations..

Key Risks

Elevated medium regulatory exposure for Inavolisib could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

Successful trial outcomes could enhance market share for inavolisib and its combinations, potentially leading to increased revenue streams in a competitive oncology market.
Upside for Inavolisib may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Inavolisib may improve if An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should monitor inavolisib's progress as it may enhance treatment options for PIK3CA-mutant breast cancer.

What Would Change This Assessment

This becomes more urgent if Follow the outcomes of the dose-escalation and expansion stages of the trial for efficacy and safety data.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Cancer Clinical Trial Eligibility Criteria: Laboratory Values
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer); Entity match (fulvestrant)
FDA document
View source
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Inavolisib
Palbociclib
Letrozole
Fulvestrant
Trastuzumab
PIK3CA-mutant Breast Cancer

Commercial impact

medium

Successful trial outcomes could enhance market share for inavolisib and its combinations, potentially leading to increased revenue streams in a competitive oncology market.

Regulatory impact

medium

The trial's results will be pivotal for future regulatory submissions and could affect labeling and compliance requirements for inavolisib and its combinations.

What to watch

Follow the outcomes of the dose-escalation and expansion stages of the trial for efficacy and safety data.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.